267 related articles for article (PubMed ID: 25557649)
1. ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model.
Nasr RR; Hmadi RA; El-Eit RM; Iskandarani AN; Jabbour MN; Zaatari GS; Mahon FX; Pisano CC; Darwiche ND
Int J Cancer; 2015 Aug; 137(3):698-709. PubMed ID: 25557649
[TBL] [Abstract][Full Text] [Related]
2. The synthetic retinoid ST1926 attenuates prostate cancer growth and potentially targets prostate cancer stem-like cells.
Bahmad HF; Samman H; Monzer A; Hadadeh O; Cheaito K; Abdel-Samad R; Hayar B; Pisano C; Msheik H; Liu YN; Darwiche N; Abou-Kheir W
Mol Carcinog; 2019 Jul; 58(7):1208-1220. PubMed ID: 30883933
[TBL] [Abstract][Full Text] [Related]
3. Antitumor Effect of the Atypical Retinoid ST1926 in Acute Myeloid Leukemia and Nanoparticle Formulation Prolongs Lifespan and Reduces Tumor Burden of Xenograft Mice.
El-Houjeiri L; Saad W; Hayar B; Aouad P; Tawil N; Abdel-Samad R; Hleihel R; Hamie M; Mancinelli A; Pisano C; El Hajj H; Darwiche N
Mol Cancer Ther; 2017 Oct; 16(10):2047-2057. PubMed ID: 28619754
[TBL] [Abstract][Full Text] [Related]
4. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
[TBL] [Abstract][Full Text] [Related]
5. Preclinical efficacy of the synthetic retinoid ST1926 for treating adult T-cell leukemia/lymphoma.
El Hajj H; Khalil B; Ghandour B; Nasr R; Shahine S; Ghantous A; Abdel-Samad R; Sinjab A; Hasegawa H; Jabbour M; Hall WW; Zaatari G; Dbaibo G; Pisano C; Bazarbachi A; Darwiche N
Blood; 2014 Sep; 124(13):2072-80. PubMed ID: 25035162
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: enhanced DNA damage response.
Zuco V; Benedetti V; De Cesare M; Zunino F
Int J Cancer; 2010 Mar; 126(5):1246-55. PubMed ID: 19676051
[TBL] [Abstract][Full Text] [Related]
7. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
8. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
9. CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
Fang Z; Jung KH; Yan HH; Kim SJ; Son MK; Rumman M; Lee H; Kim KW; Yoo HD; Hong SS
Int J Oncol; 2015 Jul; 47(1):253-61. PubMed ID: 25963192
[TBL] [Abstract][Full Text] [Related]
10. Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839.
Zanchi C; Zuco V; Lanzi C; Supino R; Zunino F
Cancer Res; 2005 Mar; 65(6):2364-72. PubMed ID: 15781651
[TBL] [Abstract][Full Text] [Related]
11. The novel atypical retinoid ST1926 is active in ATRA resistant neuroblastoma cells acting by a different mechanism.
Di Francesco AM; Meco D; Torella AR; Barone G; D'Incalci M; Pisano C; Carminati P; Riccardi R
Biochem Pharmacol; 2007 Mar; 73(5):643-55. PubMed ID: 17150196
[TBL] [Abstract][Full Text] [Related]
12. CR-LAAO antileukemic effect against Bcr-Abl(+) cells is mediated by apoptosis and hydrogen peroxide.
Burin SM; Ghisla S; Ouchida AT; Aissa AF; Coelho MG; Costa TR; Marsola AP; Pinto-Simões B; Antunes LM; Curti C; Sampaio SV; de Castro FA
Int J Biol Macromol; 2016 May; 86():309-20. PubMed ID: 26812110
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of the synthetic retinoid ST1926 on primary effusion lymphoma in vitro and in vivo models.
Karam L; Houshaymi B; Abdel-Samad R; Jaafar M; Halloum I; Pisano C; Neipel F; Darwiche N; Abou Merhi R
Oncol Rep; 2018 Feb; 39(2):721-730. PubMed ID: 29207182
[TBL] [Abstract][Full Text] [Related]
14. Effective Concentration of a Multikinase Inhibitor within Bone Marrow Correlates with In Vitro Cell Killing in Therapy-Resistant Chronic Myeloid Leukemia.
Mu C; Wu X; Ma H; Tao W; Zhang G; Xia X; Shen J; Mai J; Sun T; Sun X; Arlinghaus RB; Shen H
Mol Cancer Ther; 2016 May; 15(5):899-910. PubMed ID: 26846820
[TBL] [Abstract][Full Text] [Related]
15. Development of resistance to the atypical retinoid, ST1926, in the lung carcinoma cell line H460 is associated with reduced formation of DNA strand breaks and a defective DNA damage response.
Zuco V; Zanchi C; Lanzi C; Beretta GL; Supino R; Pisano C; Barbarino M; Zanier R; Bucci F; Aulicino C; Carminati P; Zunino F
Neoplasia; 2005 Jul; 7(7):667-77. PubMed ID: 16026646
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of the retinoid-related molecules (E)-3-(4'-hydroxy-3'-adamantylbiphenyl-4-yl)acrylic acid (ST1926) and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) in F9 teratocarcinoma: Role of retinoic acid receptor gamma and retinoid-independent pathways.
Parrella E; Giannì M; Fratelli M; Barzago MM; Raska I; Diomede L; Kurosaki M; Pisano C; Carminati P; Merlini L; Dallavalle S; Tavecchio M; Rochette-Egly C; Terao M; Garattini E
Mol Pharmacol; 2006 Sep; 70(3):909-24. PubMed ID: 16788091
[TBL] [Abstract][Full Text] [Related]
17. Cellular and pharmacological bases of the antitumor activity of a novel adamantyl retinoid, ST1926.
Pisano C; Merlini L; Penco S; Carminati P; Zunino F
J Chemother; 2004 Nov; 16 Suppl 4():74-6. PubMed ID: 15688616
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
[TBL] [Abstract][Full Text] [Related]
19. NADPH oxidases as therapeutic targets in chronic myelogenous leukemia.
Sánchez-Sánchez B; Gutiérrez-Herrero S; López-Ruano G; Prieto-Bermejo R; Romo-González M; Llanillo M; Pandiella A; Guerrero C; Miguel JF; Sánchez-Guijo F; Del Cañizo C; Hernández-Hernández A
Clin Cancer Res; 2014 Aug; 20(15):4014-25. PubMed ID: 24833663
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activities of the synthetic retinoid ST1926 in two-dimensional and three-dimensional human breast cancer models.
Aouad P; Saikali M; Abdel-Samad R; Fostok S; El-Houjeiri L; Pisano C; Talhouk R; Darwiche N
Anticancer Drugs; 2017 Aug; 28(7):757-770. PubMed ID: 28471809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
